Novartis : Mécaniquement plus délicat
>Un T2 qui devrait montrer un ralentissement mécanique - Le 21 juillet prochain, Novartis publiera ses résultats du T2 qui devraient être impactés par un ralentissement mécanique de son activité. Le T1 avait été marqué par l’augmentation d’achats anticipés par les patients avec des ordonnances couvrant une période plus longue que la normale (+4% de croissance des ventes à tcc ie 400 M$). Le management s’était vu extrêmement rassurant sur la gestion des stocks, aussi n...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.